New drug may lessen painful side effects of anal cancer therapy
NCT ID NCT03386500
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called BMX-001 added to standard radiation and chemotherapy for people newly diagnosed with anal cancer. The goal is to see if BMX-001 can reduce severe side effects like rectal bleeding and skin problems while still fighting the cancer. About 24 adults will take part to find the safest dose and measure how well it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL CANCER, SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- X-ray-free kidney stone surgery put to the test in 500-patient trial
- Could your DNA predict thyroid cancer after radiation?
- New ablation technique aims to zap heart flutter with less radiation and greater precision
- New X-Ray tech aims to cut radiation risk in gut procedures
- Which wrist access lowers radiation for heart doctors? new trial aims to find out
- New study aims to measure what matters most for kids with tough brain cancers